A detailed history of Assenagon Asset Management S.A. transactions in Abb Vie Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 2,096,858 shares of ABBV stock, worth $352 Million. This represents 0.87% of its overall portfolio holdings.

Number of Shares
2,096,858
Previous 1,315,000 59.46%
Holding current value
$352 Million
Previous $226 Million 83.59%
% of portfolio
0.87%
Previous 0.57%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$163.84 - $199.33 $128 Million - $156 Million
781,858 Added 59.46%
2,096,858 $414 Million
Q2 2024

Jul 18, 2024

BUY
$154.79 - $180.76 $154 Million - $180 Million
997,441 Added 314.1%
1,315,000 $226 Million
Q1 2024

Apr 24, 2024

SELL
$159.82 - $182.1 $292 Million - $333 Million
-1,826,351 Reduced 85.19%
317,559 $57.8 Million
Q4 2023

Jan 17, 2024

BUY
$137.6 - $154.97 $197 Million - $222 Million
1,433,236 Added 201.67%
2,143,910 $332 Million
Q3 2023

Nov 06, 2023

BUY
$133.59 - $154.65 $31.2 Million - $36.1 Million
233,403 Added 48.9%
710,674 $106 Million
Q2 2023

Jul 25, 2023

BUY
$132.51 - $164.9 $25 Million - $31.1 Million
188,558 Added 65.31%
477,271 $64.3 Million
Q1 2023

Apr 18, 2023

BUY
$144.61 - $166.54 $5.54 Million - $6.38 Million
38,335 Added 15.31%
288,713 $46 Million
Q4 2022

Jan 12, 2023

SELL
$138.31 - $165.87 $13.5 Million - $16.2 Million
-97,899 Reduced 28.11%
250,378 $40.5 Million
Q3 2022

Oct 27, 2022

SELL
$134.21 - $153.93 $38.6 Million - $44.2 Million
-287,434 Reduced 45.21%
348,277 $46.7 Million
Q2 2022

Jul 27, 2022

SELL
$137.62 - $174.96 $98,535 - $125,271
-716 Reduced 0.11%
635,711 $97.4 Million
Q1 2022

Apr 25, 2022

SELL
$131.98 - $163.75 $23.3 Million - $29 Million
-176,849 Reduced 21.75%
636,427 $103 Million
Q4 2021

Feb 01, 2022

SELL
$107.43 - $135.93 $283 Million - $358 Million
-2,631,894 Reduced 76.39%
813,276 $110 Million
Q3 2021

Oct 19, 2021

BUY
$106.4 - $120.78 $259 Million - $294 Million
2,431,209 Added 239.77%
3,445,170 $372 Million
Q2 2021

Jul 15, 2021

BUY
$105.21 - $117.21 $65.5 Million - $72.9 Million
622,096 Added 158.75%
1,013,961 $114 Million
Q1 2021

Apr 26, 2021

SELL
$102.3 - $112.62 $89.3 Million - $98.3 Million
-872,915 Reduced 69.02%
391,865 $42.4 Million
Q4 2020

Feb 01, 2021

BUY
$80.49 - $108.67 $46.5 Million - $62.8 Million
578,199 Added 84.21%
1,264,780 $136 Million
Q3 2020

Oct 07, 2020

BUY
$85.91 - $100.83 $20.5 Million - $24 Million
238,188 Added 53.12%
686,581 $60.1 Million
Q2 2020

Jul 21, 2020

BUY
$73.37 - $98.18 $18.9 Million - $25.3 Million
257,524 Added 134.92%
448,393 $44 Million
Q1 2020

Apr 17, 2020

BUY
$64.5 - $97.79 $12.3 Million - $18.7 Million
190,869 New
190,869 $14.5 Million
Q3 2019

Oct 16, 2019

SELL
$62.98 - $75.72 $50 Million - $60.2 Million
-794,413 Closed
0 $0
Q2 2019

Aug 12, 2019

BUY
$65.7 - $83.98 $52.2 Million - $66.7 Million
794,413 New
794,413 $57.8 Million
Q1 2019

Apr 26, 2019

SELL
$77.14 - $90.79 $2.22 Million - $2.61 Million
-28,792 Closed
0 $0
Q4 2018

Jan 23, 2019

SELL
$77.85 - $96.01 $55.9 Million - $68.9 Million
-717,864 Reduced 96.14%
28,792 $2.65 Million
Q3 2018

Oct 29, 2018

BUY
$88.91 - $98.84 $64.5 Million - $71.8 Million
726,012 Added 3516.82%
746,656 $70.6 Million
Q2 2018

Jul 17, 2018

SELL
$89.78 - $106.23 $15.3 Million - $18.1 Million
-170,144 Reduced 89.18%
20,644 $1.91 Million
Q1 2018

Apr 30, 2018

BUY
$92.01 - $123.21 $17 Million - $22.8 Million
184,895 Added 3137.54%
190,788 $18.1 Million
Q4 2017

Jan 25, 2018

SELL
$89.56 - $98.21 $58.8 Million - $64.4 Million
-656,121 Reduced 99.11%
5,893 $570,000
Q3 2017

Oct 18, 2017

BUY
$69.85 - $89.22 $46.2 Million - $59.1 Million
662,014
662,014 $58.8 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $297B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.